Why PALISADE-4 is a high-stakes test for Vistagen’s nose-to-brain anxiety drug strategy
Social anxiety needs faster options. Vistagen’s fasedienol now faces the Phase 3 test that could make or break its nasal-spray thesis.
How Kenox Pharmaceuticals is targeting the OINDP CDMO gap with integrated clinical manufacturing
Kenox Pharmaceuticals announces clinical manufacturing readiness for inhaled and nasal drug products. What this means for OINDP development timelines and IVBE strategy.
Polyrizon names PL-14 allergy blocker NASARIX, positioning polymer-based nasal barrier for market readiness
Find out how Polyrizon’s NASARIX branding positions the PL-14 allergy blocker for regulatory progress and future market readiness.